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The European Tobacco Products Directive (TPD) introduced a ban on characterizing flavours in cigarettes (2016), including men-
thol (2020). The longitudinal data analysis of the EUREST-PLUS International Tobacco Control (ITC) Project Europe Surveys (n = 16 
534; Wave 1 in 2016 and Wave 2 in 2018) found significant but small declines in the weighted prevalence of menthol (by 0.94%;
P = 0.041) and other flavoured cigarette use (by 1.32%; P < 0.001) following the 2016 TPD. The declines tended to be driven pri-
marily by the menthol and flavoured cigarette (MFC) smokers switching to unflavoured tobacco. Cigarette consumption declined
between waves, but there were no statistically significant difference in decline between MFC and unflavoured tobacco smokers
on smoking and cessation behaviours between the waves.
Introduction
The European Tobacco Product Directive (TPD) went into effect in May 2016 and, amongst other provisions, banned
cigarettes and roll your own with characterizing flavours within the European Union (EU). A transition period was
granted until May 2017, with the exception of menthol cigarettes that could be sold until 2020.1,2 Implementation of
the TPD offers a unique opportunity to research the profiles and behaviours of menthol and flavoured cigarette
(MFC) users in European Union Member States (EU MS).3,4
This report used data from the EUREST-PLUS ITC Europe Surveys before and after the 2016 TPD ban to assess
the changes (i) in the prevalence of different cigarette flavours [AQ5]in Europe and (ii) in the smoking status, cessa‐
tion behaviours and cigarette [AQ6]flavour preferences following the 2016 ban on cigarettes with [AQ7]characteriz‐
ing flavours, but before the 2020 ban on menthol cigarettes. [AQ8]The aim of the study was to understand whether,
given the 2016 ban, MFC smokers changed their smoking patterns.[AQ9]
Methods
Study design and population
This was a longitudinal study of data of the EUREST-PLUS ITC Europe Surveys from eight EU MS (n = 19 
691).4,5 The baseline wave preceded the 2016 TPD ban (pre-TPD), and the second wave followed it (post-TPD, but
before the implementation of the 2020 menthol flavour ban). The specific ITC waves were Wave 1 (2016) and Wave
2 (2018) of the ITC 6 European Country (6E) Survey (involving Germany, Greece, Hungary, Poland, Romania and
Spain);5 Wave 10 (2016) and Wave 11 (2017) of the ITC Netherlands (NL10) Survey;6 and data from England collec‐
ted as part of Wave 1 (2016) and Wave 2 (2018) of the Four Country Smoking and Vaping (4CV1) Survey.7 Further
details on the conceptual framework of ITC surveys can be found elsewhere.8[AQ10]
Measures
Based on their self-reported preferred cigarette brand type, respondents were classified as: menthol, other flav‐
oured, tobacco (unflavoured) and no usual flavour (did not indicate preference) users.3,4
We collected data on smoking status (pre-TPD: smoking daily/non-daily; post-TPD: smoking daily/non-daily/quit
smoking/dual use of any cigarettes and electronic cigarettes); reduction in cigarettes smoked per day (CPD) (>5 CPD
reduction, 1–5 CPD reduction, no change, 1–5 CPD increase, >5 CPD increase); quit attempts and success in the past
18 months to cover period since the baseline wave (no quit attempt/a failed quit attempt/quit smoking successfully).
Data on the following covariates were collected: age (18–24, 25–39, 40–54, 55+), nicotine dependence (as meas‐
ured by the heaviness of smoking index) (range: 0–69); sex and country.
Data analysis
All analyses were conducted using SAS-callable SUDAAN (Version 11.0.1). Descriptive statistics were estimated
to characterize smoking and quitting at pre-TPD and post-TPD.
© Copyrights 2018
To assess the changes in prevalence of the usual flavour of cigarettes smoked between pre- and post-TPD, we used
data from all respondents who provided valid information on their flavour of cigarettes smoked pre- and/or post-TPD
(n = 16 534). Weighted, binary generalized estimating equation regression models were used to estimate the adjusted
prevalence of usual flavour of cigarettes smoked pre- and post-TPD. These models controlled for sex, age and smok‐
ing status at wave of recruitment. For each flavour, an overall Model 1 was estimated; Model 2 included a coun‐
try*wave interaction effect to test whether there were differences in the adjusted prevalence of usual flavour smoked
over time within each of the eight EU MS.
To assess the changes in smoking status, as well as cessation behaviours and cigarette brand preference between
pre- and post-TPD; only respondents participating in both waves were included (n = 5612).
Results
Supplementary table S1 reports findings from Model 1 and Model 2 on changes in prevalence of different cigarette
flavours from pre-TPD to post-TPD. The prevalence of menthol cigarette use post-TPD remained highest in Poland
(11.1%), England (10.4%) and Romania (6.5%), and was lowest in Spain (1.4%). Spain was the country with the
highest prevalence of other flavoured cigarettes pre-TPD but was replaced by Poland (3.7%) post-TPD. The propor‐
tion of other flavoured cigarette use post-TPD remained lowest in the Netherlands (0.3%). Overall, the combined
prevalence of MFC use among smokers remained between 5% and 15% in all countries surveyed (and was highest in
Poland at 14.9% and England at 11.7%), with the exception of Spain, where it fell to less than 2.5%
We found significant but small declines in the prevalence of menthol use (by 0.94%; P = 0.041) and other flav‐
oured cigarette use (by 1.32%; P < 0.001) between waves in the pooled sample of all countries (see Supplementary
table S1). This decline in MFC use was primarily driven by smokers switching to unflavoured tobacco, rather than
quitting smoking. Almost 52% of menthol smokers continued to smoke menthol cigarettes, while 22.8% switched to
unflavoured tobacco. Among other flavoured cigarette smokers these figures were 11% and 62.3%, respectively (see
figure 1).
Figure 1 Changes in smoking status and preferences for the usual cigarette flavour from pre-TPD to post-TPD among smokers
who were classified as menthol, other flavours and unflavoured tobacco users at the pre-TPD wave and who were successfully
follow-up at the post-TPD wave. For further details see table 1. Note: Among menthol users at pre-TPD, by post-TPD: 51.6%
continued to smoke menthol cigarettes, 22.8% switched to unflavoured tobacco, 14% quit smoking completely, 8.0% no longer
reported having a usual flavour brand, 3.4% became dual users with e-cigarettes (together with any other cigarette brand type) and
0.3% witched to other flavoured tobacco. The width of the lanes is not to scale with the marginal proportions—the lanes for each
flavour at Wave 1 represent 100% of the particular flavours users.
Table 1 presents changes from Wave 1 and Wave in the associations of cigarette flavoured smoked and smoking
and cessation behaviours. Among smokers of menthol cigarettes 14% quit smoking altogether between waves, which
was higher than the percentage of quitters among unflavoured tobacco smokers (12%), and among other flavoured
cigarette smokers (9%). However, there was no significant association between the cigarette flavour at pre-TPD and
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quit status at follow-up. Smokers tended to reduce how much they smoked from the pre-TPD to post-TPD wave.
However, there were no statistically significant differences between MFC smokers and unflavoured tobacco post-
TPD smoking status, on whether they increased or reduced the number of cigarettes smoked per day, and in cessation
behaviour between waves.
Table 1 Change in smoking status, smoking behaviour and flavour type from pre-TPD to post-TPD
 Pre-TPD flavour type  
 Menthol Other flavoured Tobacco only (unflavoured) No usual brand  
 n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI P
Flavour type smoked post-TPD
 Menthol flav‐
oured
187 (51.6) 44.4–58.7 5 (4.8) 0.8–14.9 60 (1.3) 0.8–2.1 17 (3.0) 1.4–5.6 ***
 Other flavoured
tobacco
2 (0.3) 0.0–1.6 18 (11.0) 6.2–17.6 34 (0.8) 0.5–1.4 6 (0.9) 0.2–2.4  
 Unflavoured to‐
bacco
78 (22.8) 17.5–29.1 78 (62.3) 51.5–71.9 3450 (76.6) 74.6–78.4 270 (48.1) 41.9–54.3  
 No usual brand 30 (8.0) 4.8–12.4 14 (11.9) 6.7–18.9) 276 (6.1) 5.0–7.3 199 (34.4) 28.6–40.6  
 Dual user of any
brand (cig +  EC)
11 (3.4) 1.6–6.2 3 (1.4) 0.1–5.2 167 (4.0) 3.3–4.8 20 (3.1) 1.8–4.9  
 Quit completely 54 (14.0) 9.8–19.4 13 (8.6) 3.7–16.5 507 (11.2) 9.9–12.6 59 (10.6) 7.6–14.5  
Smoking status (post-TPD)
 Still smoking 308 (86.0) 80.6–90.2 119 (91.0) 83.1–96.0 3959 (88.0) 86.6–89.3 513 (88.8) 84.7–91.8 NS
 Quit completely 54 (14.0) 9.8–19.4 14 (9.0) 4.0–16.9 548 (12.0) 10.7–13.4 63 (11.2) 8.2–15.3  
 Menthol/other flavoured Tobacco only (unflavoured) No usual brand  
 n (%) 95% CI n (%) 95% CI n (%) 95% CI P
Smoking status (post-TPD)
 Daily 376 (77.1) 72.0–81.5 3722 (82.8) 81.2–84.3) 437 (75.0) 69.9–79.6 ***
 Non-daily 51 (10.4) 7.5–14.4 237 (5.2) 4.4–6.2 76 (13.7) 10.2–18.1  
 Quit 68 (12.5) 9.1–16.9 548 (12.0) 10.7–13.4 63 (11.2) 8.2–15.3  
Cig/day (difference between waves)
 >5 cig/day reduction 89 (19.1) 13.9–25.7 970 (22.0) 20.3–23.7 124 (21.1) 17.1–25.7 NS
 1–5 cig/day reduction 107 (20.5) 16.6–25.1 901 (20.1) 18.6–21.7 102 (19.4) 15.0–24.8  
 No change 203 (41.3) 34.5–48.4 1676 (36.1) 34.3–38.1 206 (35.4) 30.2–40.9  
 1–5 cig/day increase 68 (14.3) 10.7–18.9 618 (14.3) 12.9–15.8 72 (12.7) 9.2–17.2  
 >5 cig/day increase 25 (4.8) 2.7–7.8 311 (7.5) 6.3–8.9 60 (11.4) 8.2–15.8  
Tried to quit/quit successfully (between waves)
 Did not try to quit in past 18
months
302 (60.5) 53.9–66.8 2944 (66.1) 64.2–68.1 371 (65.7) 60.1–70.9 NS
 Tried to quit in past 18 months 125 (27.0) 21.7–33.1 1012 (21.9) 20.3–23.6 142 (23.1) 18.5–28.4  
 Quit smoking successfully (since
wave 1)




The present study provides a number of important insights. Importantly, the declines of MFC prevalence were
driven by the MFC smokers switching to unflavoured tobacco, rather than quitting smoking. This was the case of
62% flavoured cigarette users, as expected given the ban, but also 23% of menthol cigarettes users—a more surpris‐
ing finding given that the ban on menthol cigarettes had not taken effect yet. Moreover, MFC smokers were not more
likely to quit smoking or reduce cigarette consumption post-TPD than smokers of unflavoured cigarettes. Further‐
more, despite the 2016 TPD ban, a small minority of smokers still smoked flavoured cigarettes, which could be due
to the transition period in ban implementation.1 Finally, on the whole in the eight EU MS there was a significant but
very small decline in the MFC prevalence immediately following the TPD ban, although the trends of use were dif‐
ferent in each country.
These findings should be interpreted with caution and in the wider context. The TPD ban of cigarette flavourings
was motivated principally by the need to reduce the appeal of cigarettes and smoking initiation among youth, whereas
this sample at recruitment included only adult smokers. Furthermore, while the EUREST-PLUS ITC Europe Surveys
offer the best data available to research these policies, as it is the largest cohort study in Europe evaluating the TPD,
the study has some limitations, including a considerable loss-to-follow-up in several of EUREST-Plus countries,
which could have introduced selection bias.10
Moreover, the TPD does not include specific measures directed at increasing the predictors of quit attempt suc‐
cess, such as the use of evidence-based cessation support by smokers, or provisions indicated in Article 14 of the
World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC).11,12 Without these addi‐
tional measures we may not be able to see changes in smoking prevalence at short term. Continued monitoring is
needed to ascertain the long-term impact of TPD, including if the MFC smokers who moved to unflavoured cigarettes
will be more likely to quit as a next step.
Crucially, there remains an opportunity for tobacco control prior to the implementation of the 2020 ban on men‐
thol cigarettes. Countries with relatively high menthol use among smokers (especially Poland and England, but also
the Netherlands, Romania and Hungary, where prevalence of menthol is above 5%) should strengthen stop smoking
campaigns alongside the menthol cigarette ban, so as to aid cessation.
Supplementary data
Supplementary data are available at EURPUB online.
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